Amgen to Open Technology & Innovation Centre in Hyderabad
US biotech giant Amgen has announced plans to establish a new technology and innovation center in Hyderabad, marking a significant expansion of its global operations. The center, set to be operational by Q4 2024, will be located in HITEC City, Hyderabad's premier tech hub. The facility will occupy six floors of the RMZ Spire Tower and has the capacity to accommodate up to 3,000 employees.
Amgen India will focus on building and accelerating new technology solutions and digital capabilities, enhancing efficiencies across the enterprise. The center will initially concentrate on artificial intelligence (AI), data science, life sciences, and other key areas, with plans to expand its global capabilities over time.
Som Chattopadhyay has been appointed as the national executive to lead Amgen’s operations in India, overseeing the expansion of the company's presence in the region.
David M. Reese, Amgen’s executive vice president and chief technology officer, emphasized the importance of the new site, stating, "At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency. Establishing this new site in India, a country known for its world-class technology and life sciences talent, marks a significant step forward in our journey to serve patients”.
Amgen, headquartered in California, is one of the world's leading biotech companies, with revenues of $28.2 billion in 2023. The company employs nearly 27,000 people globally and operates in around 100 countries, including India.
The establishment of Amgen's new center in Hyderabad underscores the city's growing reputation as a hub for innovation and technology. Welcoming the investment, Chief Minister Anumula Revanth Reddy highlighted Hyderabad's appeal to multinational pharma and medtech companies.
In recent months, several global companies have announced significant investments in their Global Capability Centers (GCCs) in India. Sanofi has committed Rs 3,600 crore to expand its Hyderabad operations, while AstraZeneca plans to invest Rs 250 crore to grow its Global Innovation and Technology Centre in Chennai, creating approximately 1,300 skilled jobs by 2025. Novartis, an early entrant into India, employs over 8,100 associates, with the majority working at its Hyderabad GCC.
Other multinational companies, including Bristol Myers Squibb, Bayer, Merck, Novo Nordisk, Medtronic, Siemens Healthineers, and GE Healthcare, have also established GCCs in India to leverage the country’s talent, particularly in the technology domain. These centers play a crucial role in supporting global operations, optimizing manufacturing processes, and advancing drug discovery and clinical trials.
